



**HAL**  
open science

**P16-52. HIV-activated human plasmacytoid DCs induce  
Tregs through an indoleamine  
2,3-dioxygenase-dependent mechanism**

O Manches, D Munn, A Fallahi, J Lifson, Laurence Chaperot, Joël Plumas, N  
Bhardwaj

► **To cite this version:**

O Manches, D Munn, A Fallahi, J Lifson, Laurence Chaperot, et al.. P16-52. HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism. *Retrovirology*, 2009, 6 (Suppl 3), pp.P281. inserm-00651123

**HAL Id: inserm-00651123**

**<https://inserm.hal.science/inserm-00651123>**

Submitted on 12 Dec 2011

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Poster presentation

Open Access

## PI6-52. HIV-activated human plasmacytoid DCs induce Tregs through an indoleamine 2,3-dioxygenase-dependent mechanism

O Manches\*<sup>1</sup>, D Munn<sup>2</sup>, A Fallahi<sup>1</sup>, J Lifson<sup>3</sup>, L Chaperot<sup>4</sup>, J Plumas<sup>4</sup> and N Bhardwaj<sup>1</sup>

Address: <sup>1</sup>Cancer Institute, New York University Langone Medical Center, New York, USA, <sup>2</sup>Medical College of Georgia, Augusta, GA, USA, <sup>3</sup>National Cancer Institute, Frederick, USA and <sup>4</sup>INSERM U823, EFS Rhone-Alpes, La Tronche, France

\* Corresponding author

from AIDS Vaccine 2009  
Paris, France. 19–22 October 2009

Published: 22 October 2009

Retrovirology 2009, 6(Suppl 3):P281 doi:10.1186/1742-4690-6-S3-P281

This abstract is available from: <http://www.retrovirology.com/content/6/S3/P281>

© 2009 Manches et al; licensee BioMed Central Ltd.

### Background

Plasmacytoid dendritic cells (pDC) are crucial cells implicated in anti-viral immune responses. On recognizing HIV, they become activated, secreting high amounts of IFN $\alpha$  and inflammatory cytokines, thereby potentiating anti-viral innate and adaptive immune responses. However, the role of pDC in adaptive immunity is still debated. Several studies have documented a role for activated pDC in the induction of CD4<sup>+</sup> or CD8<sup>+</sup> regulatory T cells (Treg), both in vitro and in vivo. A direct correlation between CD8<sup>+</sup> T cell activation levels and disease progression levels has been confirmed in many studies. We investigated here whether HIV-stimulated pDC can regulate the levels of immune activation by promoting the differentiation of regulatory CD4<sup>+</sup> T cells.

### Methods

Freshly purified pDC from normal donors (New York Blood Bank) were incubated for 7 days with purified allogeneic CD4<sup>+</sup> CD25<sup>-</sup> T cells, and their suppressive activity measured in a secondary proliferative assay. CD86/CD83 expression and cytokine secretion by monocyte-derived DC (moDC) induced by LPS or R848 were measured in presence or absence of CD3-activated Treg. siRNA knock-down of NIK and IKK $\alpha$  was performed on the leukemic pDC line GEN2.2 and expression of IDO was monitored at the RNA and protein level.

### Results

HIV-stimulated pDC were found to induce the differentiation of Treg from naive CD4<sup>+</sup> T cells, in an indoleamine 2,3 dioxygenase (IDO)-dependent way. Furthermore, pDC-induced Treg could suppress the Toll-Like Receptor (TLR)-mediated maturation of moDC, partially through CTLA-4 interaction with CD80/CD86. We further show that TLR triggering induces the activation of IDO through the non-canonical NF- $\kappa$ B pathway, as evidenced by knocking-down the expression of NIK and IKK $\alpha$ .

### Conclusion

This study reveals what we believe to be a novel mechanism by which pDC may regulate and potentially limit anti-HIV immune responses, and identifies a potential target for clinical intervention.